MyFiziq teams up with Tinjoy as it eyes off China
Hey! Looks like you have stumbled on the section of our website where we have archived articles from our old business model.
In 2019 the original founding team returned to run Next Investors, we changed our business model to only write about stocks we carefully research and are invested in for the long term.
The below articles were written under our previous business model. We have kept these articles online here for your reference.
Our new mission is to build a high performing ASX micro cap investment portfolio and share our research, analysis and investment strategy with our readers.
Click Here to View Latest Articles
In a development that has driven MyFiziq Limited’s (ASX:MYQ) share price above the $2.00 mark, the company has concluded a Terms Sheet, granting Tinjoy access and distribution rights to the MyFiziq CompleteScan platform, which will be integrated into Tinjoy’s “WinScan Digital Health Platform” (WinScan).
MyFiziq’s shares have performed extremely strongly in February, having doubled since the start of the month, surpassing’s 2018 high of about $1.50 to hit today’s all-time high.
Consequently, it would appear that technical investors see significant upside from a charting point of view, and with material operational developments in the pipeline, this recent momentum looks set to continue.
The following chart from walletinvestor.com suggests there is upside beyond the $2.00 per share mark in the near term.
It is worth noting that MyFiziq’s pushed beyond the $2.00 mark has occurred earlier than projected, suggesting that the chart predictions may be on the conservative side.
Tinjoy has captive audience of 28 million in China
Harking back to today’s news, WinScan was launched by Tinjoy in 2020 to expand the company’s digital presence in China.
Tinjoy has a captive audience of over 28 million consumers within China, and the WinScan offering has been specifically designed in its workflow to accommodate the partner and community needs it addresses.
Tinjoy has a 500 person call centre in Nanning growing to 1,000 in the coming months, and the call centre will play a significant role in achieving the agreed initial user target of 1,000,000 monthly active users.
WinScan specialises in multiple segments of personal and population health, as well as medical and preventative care using a well-developed digital engagement platform, purpose-built for China and the ease of navigation to local communities.
WinScan supports care across, wellness, preventive health, and precision nutrition, supplying measurable data analytics across omni-channel engagements.
The platform’s evidence-based functionalities are used for early-detection and health assessments, with a primary focus on identifying individuals at risk of chronic disease.
Forging a long-term partnership
MyFiziq and Tinjoy will be combining their respective platforms for release across multiple market segments within China, and chief executive Vlado Bosanac highlighted the fact that both parties had a view to establishing a long-term partnership saying, ‘’Tinjoy has developed a tailored approach to better health outcomes and engagement in corporate, community and telehealth platforms.
"Not only does it provide a broad and conclusive offering, it also generates comprehensive data analytics to the partner or end-users.
"I am pleased Tinjoy views the agreement as a long-term partnership, with their openness to MyFiziq acquiring a substantive holding if the platform achieves monthly users of 5 million or more.
"The agreed consideration would be well under the monthly revenue MyFiziq would see based on the pricing we have structured in consultation with Tinjoy.”
Whilst undertaking the integration, management’s initial focus will be to train 500 of the call centre team members to deliver the offering to the already-harnessed communities within the pre-existing Tinjoy customer base.
Tinjoy will be producing appropriate media to demonstrate how to use the technology, which will initially include BodyScan, FaceScan, COVID symptoms check, and later DermaScan.
The companies are targeting a release of the combined solution in the initial offering, providing individuals with the ability to take a single scan in any one of the 3-preliminary scans by the September quarter of 2021.
General Information Only
S3 Consortium Pty Ltd (S3, ‘we’, ‘us’, ‘our’) (CAR No. 433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information and is for informational purposes only. Any advice is general advice only. Any advice contained in this article does not constitute personal advice and S3 has not taken into consideration your personal objectives, financial situation or needs. Please seek your own independent professional advice before making any financial investment decision. Those persons acting upon information contained in this article do so entirely at their own risk.
Conflicts of Interest Notice
S3 and its associated entities may hold investments in companies featured in its articles, including through being paid in the securities of the companies we provide commentary on. We disclose the securities held in relation to a particular company that we provide commentary on. Refer to our Disclosure Policy for information on our self-imposed trading blackouts, hold conditions and de-risking (sell conditions) which seek to mitigate against any potential conflicts of interest.
Publication Notice and Disclaimer
The information contained in this article is current as at the publication date. At the time of publishing, the information contained in this article is based on sources which are available in the public domain that we consider to be reliable, and our own analysis of those sources. The views of the author may not reflect the views of the AFSL holder. Any decision by you to purchase securities in the companies featured in this article should be done so after you have sought your own independent professional advice regarding this information and made your own inquiries as to the validity of any information in this article.
Any forward-looking statements contained in this article are not guarantees or predictions of future performance, and involve known and unknown risks, uncertainties and other factors, many of which are beyond our control, and which may cause actual results or performance of companies featured to differ materially from those expressed in the statements contained in this article. S3 cannot and does not give any assurance that the results or performance expressed or implied by any forward-looking statements contained in this article will actually occur and readers are cautioned not to put undue reliance on forward-looking statements.
This article may include references to our past investing performance. Past performance is not a reliable indicator of our future investing performance.